Vaxcell-Bio Therapeutics Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 86

Employees

  • Stock Symbol
  • 323990

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $2.79
  • (As of Thursday Closing)

Vaxcell-Bio Therapeutics General Information

Description

Vaxcell-Bio Therapeutics is a bio-technology company engaged in the development of Cell-based and Protein-based Immunotherapeutics for the treatment of cancer.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 98-1 Sandan-gil
  • Hwasun-eup
  • Hwasun-gun, Jeollanam-do 58141
  • South Korea
+82
Primary Industry
Drug Discovery
Stock Exchange
KRX
Vertical(s)
Corporate Office
  • 98-1 Sandan-gil
  • Hwasun-eup
  • Hwasun-gun, Jeollanam-do 58141
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vaxcell-Bio Therapeutics Stock Performance

As of 19-Nov-2026, Vaxcell-Bio Therapeutics’s stock price is $2.79. Its current market cap is $64.6M with 23.2M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.79 $2.73 $2.32 - $8.05 $64.6M 23.2M 260K -$0.44

Vaxcell-Bio Therapeutics Financials Summary

As of 30-Jun-2026, Vaxcell-Bio Therapeutics has a trailing 12-month revenue of $4.49M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 65,115 144,798 136,612 388,684
Revenue 4,487 4,958 1,392 10
EBITDA (9,183) (8,686) (8,467) (8,403)
Net Income (10,279) (9,374) (7,786) (7,858)
Total Assets 38,031 46,460 52,237 65,944
Total Debt 1,008 1,381 1,540 280
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vaxcell-Bio Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vaxcell-Bio Therapeutics‘s full profile, request access.

Request a free trial

Vaxcell-Bio Therapeutics Patents

Vaxcell-Bio Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026101191-A1 Novel vascularization inhibitor and use thereof Pending 11-Nov-2024
WO-2026042913-A1 Composition for treating cancer in tumor-affected dogs comprising recombinant canine interleukin-15 Pending 22-Aug-2024
WO-2025254457-A1 Epcam and cd3-bispecific antibody fragment having affinity-modulated mutant Pending 04-Jun-2024
WO-2025254456-A1 Nanobody-scfv antibody fragment bispecific for epcam and cd3 Pending 04-Jun-2024
WO-2025254458-A1 Proteasome inhibitor comprising lactone structure Pending 04-Jun-2024
To view Vaxcell-Bio Therapeutics’s complete patent history, request access »

Vaxcell-Bio Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vaxcell-Bio Therapeutics Investments & Acquisitions (4)

Vaxcell-Bio Therapeutics’s most recent deal was a Later Stage VC with CNCure biotech for . The deal was made on 25-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CNCure biotech 25-Jun-2026 Later Stage VC Drug Discovery
MetaImmuneTech 04-Dec-2025 Seed Round Diagnostic Equipment
AL Biotech 01-Mar-2025 Merger/Acquisition Drug Discovery
SH Pharm 14-Oct-2024 Merger/Acquisition Pharmaceuticals
To view Vaxcell-Bio Therapeutics’s complete investments and acquisitions history, request access »

Vaxcell-Bio Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.98 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Vaxcell-Bio Therapeutics’s complete esg history, request access »

Vaxcell-Bio Therapeutics FAQs

  • When was Vaxcell-Bio Therapeutics founded?

    Vaxcell-Bio Therapeutics was founded in 2010.

  • Where is Vaxcell-Bio Therapeutics headquartered?

    Vaxcell-Bio Therapeutics is headquartered in Hwasun-gun, South Korea.

  • What is the size of Vaxcell-Bio Therapeutics?

    Vaxcell-Bio Therapeutics has 86 total employees.

  • What industry is Vaxcell-Bio Therapeutics in?

    Vaxcell-Bio Therapeutics’s primary industry is Drug Discovery.

  • Is Vaxcell-Bio Therapeutics a private or public company?

    Vaxcell-Bio Therapeutics is a Public company.

  • What is Vaxcell-Bio Therapeutics’s stock symbol?

    The ticker symbol for Vaxcell-Bio Therapeutics is 323990.

  • What is the current stock price of Vaxcell-Bio Therapeutics?

    As of 19-Nov-2026 the stock price of Vaxcell-Bio Therapeutics is $2.79.

  • What is the current market cap of Vaxcell-Bio Therapeutics?

    The current market capitalization of Vaxcell-Bio Therapeutics is $64.6M.

  • What is Vaxcell-Bio Therapeutics’s current revenue?

    The trailing twelve month revenue for Vaxcell-Bio Therapeutics is $4.49M.

  • What is Vaxcell-Bio Therapeutics’s annual earnings per share (EPS)?

    Vaxcell-Bio Therapeutics’s EPS for 12 months was -$0.44.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process